한빛사 논문
Fraser Soares1,*, Branson Chen2,3,*, Jong Bok Lee2,4,*, Musaddeque Ahmed1,*, Dalam Ly2,4, Enoch Tin2,4, Hyeonjeong Kang2, Yong Zeng1, Nayeema Akhtar1, Mark D. Minden3, Housheng Hansen He1,5, Li Zhang1,2,4
1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. 2Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, 9 Canada. 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, 11 Canada. 4Department of Immunology, University of Toronto, Toronto, Ontario, Canada. 5Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
* These authors contributed equally to this work.
Co-Corresponding authors: Dr. Li Zhang, Dr. Housheng Hansen He
Abstract
Acute myeloid leukemia (AML) remains a devastating disease in need of new therapies to improve patient survival. Targeted, adoptive T cell therapies have achieved impressive clinical outcomes in some B-cell leukemias and lymphomas but not in AML. Double negative T cells (DNTs) effectively kill blast cells from the majority of AML patients and are now being tested in clinical trials. However, AML blasts obtained from ~30% of patients show resistance to DNT cell-mediated cytotoxicity; the markers or mechanisms underlying this resistance have not been elucidated. Here, we used a targeted CRISPR/Cas9 screen to identify genes that confer susceptibility of AML cells to DNT cell therapy. Inactivation of the SAGA deubiquitinating complex components sensitized AML cells to DNT-mediated cytotoxicity. In contrast, CD64 inactivation resulted in resistance to DNT-mediated cytotoxicity. Importantly, the level of CD64 expression strongly correlated with the sensitivity of AML cells to DNT cell treatment. Furthermore, the ectopic expression of CD64 overcame AML resistance to DNTs both in vitro and in vivo. Altogether, our data demonstrate the utility of CRISPR/Cas9 screens to uncover mechanisms underlying the sensitivity to DNT cell therapy and suggest CD64 as a predictive marker for response in AML patients.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기